(2S,3R,4R,5S,6S)-2-(4-chloro-3-{4-[(R)-(tetrahydro-furan-3-yl)oxy]-benzyl}-phenyl)-6-methoxy-tetrahydro-pyran-3,4,5-triol | 1018899-68-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3R,4R,5S,6S)-2-(4-chloro-3-{4-[(R)-(tetrahydro-furan-3-yl)oxy]-benzyl}-phenyl)-6-methoxy-tetrahydro-pyran-3,4,5-triol
• 英文别名: (2S,3R,4R,5S,6S)-2-(4-Chloro-3-(4-((3R)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-methoxytetrahydro-2H-pyran-3,4,5-triol；(2S,3R,4R,5S,6S)-2-[4-chloro-3-[[4-[(3R)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-methoxyoxane-3,4,5-triol
• CAS: 1018899-68-7
• 化学式: C₂₃H₂₇ClO₇
• 分子量: 450.916
• InChiKey: SUXVCWLPMZFCBT-IYGHGDFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  97.6
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• COMPOSITIONS COMPRISING AND METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2
  申请人：CHEN Jinling

  公开号：US20120172320A1

  公开（公告）日：2012-07-05

  Pharmaceutical dosage forms useful for improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as methods of their manufacture.

  本发明揭示了用于改善心血管和/或代谢健康的药物剂型，特别是用于治疗2型糖尿病患者的药物剂型，以及其制造方法。
• Phlorizin analogs as SGLT2 inhibitors
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2308841A2

  公开（公告）日：2011-04-13

  Compounds are disclosed that are inhibitors of SGLT2 and thus may be useful for the treatment of diseases and disorders such as diabetes and obesity.

  所公开的化合物是 SGLT2 的抑制剂，因此可用于治疗糖尿病和肥胖症等疾病。
• INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2089361B1

  公开（公告）日：2011-01-26
• COMBINATIONS COMPRISING 6-BENZYLPHENYL-2- SULFURTERAHYDROPYRAN-3,4,5-TRIOL DERIVATIVES AS INHIBITORS OF SODIUM -GLUCOSE COTRANSPORTERS 1 AND 2 FOR USE IN DIABETIC PATIENTS
  申请人：Lexicon Pharmaceuticals, Inc.

  公开号：EP2542236B1

  公开（公告）日：2016-10-26
• METHODS OF USING INHIBITORS OF SODIUM-GLUCOSE COTRANSPORTERS 1 AND 2
  申请人：Brown Philip Manton

  公开号：US20110218159A1

  公开（公告）日：2011-09-08

  Methods of improving the cardiovascular and/or metabolic health of patients, particularly those suffering from type 2 diabetes, are disclosed, as well as compounds and pharmaceutical compositions useful therein.